Ketotifen
![]() |
|
Clinical data | |
---|---|
Trade names | Zaditor[1] |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a604033 |
Pregnancy category |
|
Routes of administration |
Oral (tablets), ophthalmic solution |
ATC code | |
Legal status | |
Legal status |
|
Pharmacokinetic data | |
Bioavailability | 60% |
Protein binding | 75% |
Metabolism | Hepatic |
Biological half-life | 12 hours |
Identifiers | |
|
|
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
ECHA InfoCard | 100.047.349 |
Chemical and physical data | |
Formula | C19H19NOS |
Molar mass | 309.426 g/mol |
3D model (Jmol) | |
|
|
|
|
(verify) |
Ketotifen is a first-generation noncompetitive H1-antihistamine and mast cell stabilizer. It is most commonly sold as a salt with fumaric acid, ketotifen fumarate, and is available in two forms. In its ophthalmic form, it is used to treat allergic conjunctivitis.[2] In its oral form, it is used to prevent asthma attacks or Anaphylaxis, as well as various mast cell, allergic-type disorders.[3][4][5][6][7]
Uses[edit]
Ketotifen relieves and prevents eye itchiness and/or irritation associated with most seasonal allergies. It starts working within minutes after administering the drops. The drug has not been studied in children under three.[2] The mean elimination half life is 12 hours.[8] Besides its anti-histaminic activity, it is also a functional leukotriene antagonist and a phosphodiesterase inhibitor.
"[O]ral ketotifen has been used in patients with asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, chronic urticaria, cold-induced urticaria, cholinergic urticaria, exercise-induced urticaria, [systemic mast cell disease including mastocytosis, MCAS, allergic and nonallergic anaphylaxis, angioedema], and food allergy in Canada, Europe, and Mexico." Now available via prescription at US compounding pharmacies: "For adults and older children with asthma or allergic disease, the recommended dose of ketotifen is 1 mg twice daily." "FDA staff did recommend more extensive evaluations for management of urticaria."[5][6]
The drug may also help relieve the symptoms of irritable bowel syndrome.[9]
Side effects[edit]
This section does not cite any sources. (June 2014) (Learn how and when to remove this template message) |
Side effects include drowsiness, weight gain, dry mouth, irritability, and increased nosebleeds.
Brands[edit]
Ketotifen is marketed under many brand names worldwide.[10]
See also[edit]
References[edit]
- ^ http://www.webmd.com/drugs/2/drug-17484/zaditor-opht/details[full citation needed]
- ^ a b Zaditor prescribing information Novartis
- ^ Sokol, Kristin C.; Amar, Neil K.; Starkey, Jonathan; Grant, J. Andrew (2013). "Ketotifen in the management of chronic urticaria: Resurrection of an old drug". Annals of Allergy, Asthma & Immunology. 111 (6): 433–6. doi:10.1016/j.anai.2013.10.003. PMC 4309375
. PMID 24267353.
- ^ Shawky, Rabah M.; Seifeldin, Neveen S. (2015). "The relation between antihistamine medication during early pregnancy & birth defects". Egyptian Journal of Medical Human Genetics. 16 (4): 287–90. doi:10.1016/j.ejmhg.2015.04.003.
- ^ a b Zuberbier, Torsten (2012). "A Summary of the New International EAACI/GA2LEN/EDF/ WAO Guidelines in Urticaria". World Allergy Organization Journal. 5 (1): S1–S5. doi:10.1186/1939-4551-5-S1-S1.
- ^ a b Zuberbier, T.; Asero, R.; Bindslev-Jensen, C.; Walter Canonica, G.; Church, M. K.; Giménez-Arnau, A. M.; Grattan, C. E. H.; Kapp, A.; Maurer, M.; Merk, H. F.; Rogala, B.; Saini, S.; Sánchez-Borges, M.; Schmid-Grendelmeier, P.; Schünemann, H.; Staubach, P.; Vena, G. A.; Wedi, B. (2009). "EAACI/GA²LEN/EDF/WAO guideline: Management of urticaria". Allergy. 64 (10): 1427–43. doi:10.1111/j.1398-9995.2009.02178.x. PMID 19772513.
- ^ Li, Zhenhong; Celestin, Jocelyn (February 23, 2015). Ketotifen: A Role in the Treatment of Idiopathic Anaphylaxis. American Academy of Allergy, Asthma & Immunology Annual Meeting. Houston.
- ^ Grahnén, A.; Lönnebo, A.; Beck, O.; Eckernäs, S-Å; Dahlström, B.; Lindström, B. (1992). "Pharmacokinetics of ketotiffn after oral administration to healthy male subjects". Biopharmaceutics & Drug Disposition. 13 (4): 255–62. doi:10.1002/bdd.2510130404. PMID 1600111.
- ^ Klooker, T. K.; Braak, B.; Koopman, K. E.; Welting, O.; Wouters, M. M.; Van Der Heide, S.; Schemann, M.; Bischoff, S. C.; Van Den Wijngaard, R. M.; Boeckxstaens, G. E. (2010). "The mast cell stabiliser ketotifen decreases visceral hypersensitivity and improves intestinal symptoms in patients with irritable bowel syndrome". Gut. 59 (9): 1213–21. doi:10.1136/gut.2010.213108. PMID 20650926.
- ^ drugs.com International availability of ketofin Page accessed April 21, 2015